Carbidopa/levodopa - Hong Kong WD Pharmaceutical
Alternative Names: WD 1603Latest Information Update: 28 Sep 2023
At a glance
- Originator Hong Kong WD Pharmaceutical
- Developer Hong Kong WD Pharmaceutical; Shanghai WD Pharmaceutical
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in India (PO, Controlled release)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Canada (PO, Controlled release)
- 29 Oct 2021 Phase-I clinical trials in Parkinson's disease (In volunteers, In adults) in India (PO)(NCT05128175)